cetuximab + docetaxel + gemcitabine

Cetuximab + docetaxel + gemcitabine is a combination regimen consisting of three anticancer agents used primarily in the treatment of advanced or unresectable non-small cell lung cancer (NSCLC). Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth factor receptor (EGFR), inhibiting downstream signaling pathways involved in tumor cell proliferation and survival. Docetaxel is a taxane-class small molecule chemotherapeutic that disrupts microtubule function, leading to inhibition of mitosis and apoptosis. Gemcitabine is a nucleoside analog that interferes with DNA synthesis, resulting in cytotoxicity to rapidly dividing cells. This combination has been studied for its efficacy and safety profile, showing activity similar to chemotherapy alone but with notable risks such as severe hypersensitivity reactions associated with cetuximab[1][8].